十九大报告为医药企业带来的那些利好

2017-10-20 佚名 新浪医药新闻

18日,中国共产党第十九次全国代表大会正式开幕。会上,题为《决胜全面建成小康社会 夺取新时代中国特色社会主义伟大胜利》的报告,有多个部分涉及医药产业领域,笔者着重从各个方面,对相关涉及内容进行简析,供大家参考。1、原文:坚持去产能、去库存、去杠杆、降成本、补短板,优化存量资源配置,扩大优质增量供给,实现供需动态平衡。—— 深化供给侧结构性改革解读:总体来看,去除大量的、无效的文号是关键因素。其

18日,中国共产党第十九次全国代表大会正式开幕。会上,题为《决胜全面建成小康社会 夺取新时代中国特色社会主义伟大胜利》的报告,有多个部分涉及医药产业领域,笔者着重从各个方面,对相关涉及内容进行简析,供大家参考。

1、原文:坚持去产能、去库存、去杠杆、降成本、补短板,优化存量资源配置,扩大优质增量供给,实现供需动态平衡。—— 深化供给侧结构性改革

解读:总体来看,去除大量的、无效的文号是关键因素。其中,最关键的,就是开展化药仿制药一致性评价,坚定不移地提高国产仿制药质量水平,让广大消费者能够享受质优价廉的好药。

2、原文:激发和保护企业家精神,鼓励更多社会主体投身创新创业。建设知识型、技能型、创新型劳动者大军,弘扬劳模精神和工匠精神,营造劳动光荣的社会风尚和精益求精的敬业风气。—— 深化供给侧结构性改革

解读:日前,《中共中央国务院关于营造企业家健康成长环境弘扬优秀企业家精神更好发挥企业家作用的意见》(中发﹝2017﹞25号文件)已经正式公布。以文件形式对企业家和企业家精神的地位和价值予以肯定,是增强经济发展活力的现实要求,也是对医药行业企业家关切做出的有力支持。而建设“知识型、技能型、创新型”劳动大军,对药品行业而言,则意味着传统的销售模式要向药品价值本身回归,医药企业要从“三型合一”人才队伍建设角度出发,培养更多的复合型的高端人才。

3、原文:深化科技体制改革,建立以企业为主体、市场为导向、产学研深度融合的技术创新体系,加强对中小企业创新的支持,促进科技成果转化。倡导创新文化,强化知识产权创造、保护、运用。——加快建设创新型国家

解读:“产学研”三位一体,将是成就中国医药行业持续健康快速发展的必经之路。中小企业要抓住机遇,在药品科技成果转化方面,要勇于创新、敢于创新,前方大有所为。

4、原文:全面实施市场准入负面清单制度,清理废除妨碍统一市场和公平竞争的各种规定和做法,支持民营企业发展,激发各类市场主体活力。深化商事制度改革,打破行政性垄断,防止市场垄断,加快要素价格市场化改革,放宽服务业准入限制,完善市场监管体制。——加快完善社会主义市场经济体制

解读:此次报告,再次明确了:国家实行市场准入负面清单制度,将会强化行政资源用于加强市场事中、事后监管,减少市场中“劣币驱逐良币”的现象。相信这将会极大地营造广大医药行业从业者公开、公平、公正的竞争氛围,给医药市场注入强劲的发展动力。

5、原文:坚持按劳分配原则,完善按要素分配的体制机制,促进收入分配更合理、更有序。鼓励勤劳守法致富,扩大中等收入群体,增加低收入者收入,调节过高收入,取缔非法收入。——提高就业质量和人民收入水平

解读:勤劳守法致富是医药行业从业者的天条!《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》中第二十七条明确指出:“药品上市许可持有人须将医药代表名单在食品药品监管部门指定的网站备案。禁止医药代表承担药品销售任务,禁止向医药代表或相关企业人员提供医生个人开具的药品处方数量。以医药代表名义进行药品经营活动的,按非法经营药品查处”。目前,上海各地正在通过相关政策的制定,抓紧落地医药代表备案制度,这本身就从一个角度说明了医药行业从业者走向标准化和合规是必然趋势,当一切都规范化、标准化,那么在同一个起跑线上,谁付出的努力更多,谁就会有丰硕的收获。这才是真正的勤劳致富!

6、原文:完善城镇职工基本养老保险和城乡居民基本养老保险制度,尽快实现养老保险全国统筹。完善统一的城乡居民基本医疗保险制度和大病保险制度。完善失业、工伤保险制度。——加强社会保障体系建设

解读:相关政策的出台,有利于健全和完善统筹城乡社会保障体系,同时有利于促进人口和劳动力流动,是社会公平正义的一种积极体现。当然,在城镇一体化的过程中,医药行业要敏锐捕捉相关政策释放的红利,积极开拓市场,这无疑又是一大利好。

7、原文:深化医药卫生体制改革,全面建立中国特色基本医疗卫生制度、医疗保障制度和优质高效的医疗卫生服务体系,健全现代医院管理制度。加强基层医疗卫生服务体系和全科医生队伍建设。全面取消以药养医,健全药品供应保障制度。——实施健康中国战略

解读:得益于医改的持续推进,医疗服务和公共卫生服务能力不断提升,人民健康水平不断提高。更为重要的是,中央全面取消以药养医的决心坚定不移,看病消费负担将持续减轻。

8、原文:坚持中西医并重,传承发展中医药事业。支持社会办医,发展健康产业。促进生育政策和相关经济社会政策配套衔接,加强人口发展战略研究。积极应对人口老龄化,构建养老、孝老、敬老政策体系和社会环境,推进医养结合,加快老龄事业和产业发展。——实施健康中国战略

解读:中央积极支持中医药事业,对广大中药企业来说,中医药产业发展将再次迎来黄金时期,春天已然来了!同时,随着医养结合的快速推进,大健康领域已经成为新时代下医药企业双轮驱动的又一个发力点与主战场。


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1935721, encodeId=e6351935e2128, content=<a href='/topic/show?id=cda0352e61c' target=_blank style='color:#2F92EE;'>#医药企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35276, encryptionId=cda0352e61c, topicName=医药企业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Thu May 17 18:58:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636276, encodeId=f7a416362e600, content=<a href='/topic/show?id=312b35662d6' target=_blank style='color:#2F92EE;'>#十九大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35662, encryptionId=312b35662d6, topicName=十九大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219a22610756, createdName=12498974m58暂无昵称, createdTime=Sun Sep 23 23:58:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256221, encodeId=45842562216e, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Oct 26 22:25:45 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255611, encodeId=321d255611fd, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Tue Oct 24 13:13:54 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255157, encodeId=a30325515e79, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Oct 22 20:07:06 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409126, encodeId=2f691409126a4, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Oct 22 02:58:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456131, encodeId=0fa31456131c9, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Oct 22 02:58:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254689, encodeId=5dbe2546895d, content=总体来看.去除大量的.无效的文号是关键因素.其中.最关键的.就是开展化药仿制药一致性评价.坚定不移地提高国产仿制药质量水平.让广大消费者能够享受质优价廉的好药., beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Fri Oct 20 23:25:58 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254683, encodeId=f7ac2546833a, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Oct 20 23:21:28 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254619, encodeId=693c25461901, content=好消息.值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Fri Oct 20 16:29:36 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1935721, encodeId=e6351935e2128, content=<a href='/topic/show?id=cda0352e61c' target=_blank style='color:#2F92EE;'>#医药企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35276, encryptionId=cda0352e61c, topicName=医药企业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Thu May 17 18:58:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636276, encodeId=f7a416362e600, content=<a href='/topic/show?id=312b35662d6' target=_blank style='color:#2F92EE;'>#十九大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35662, encryptionId=312b35662d6, topicName=十九大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219a22610756, createdName=12498974m58暂无昵称, createdTime=Sun Sep 23 23:58:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256221, encodeId=45842562216e, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Oct 26 22:25:45 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255611, encodeId=321d255611fd, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Tue Oct 24 13:13:54 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255157, encodeId=a30325515e79, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Oct 22 20:07:06 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409126, encodeId=2f691409126a4, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Oct 22 02:58:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456131, encodeId=0fa31456131c9, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Oct 22 02:58:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254689, encodeId=5dbe2546895d, content=总体来看.去除大量的.无效的文号是关键因素.其中.最关键的.就是开展化药仿制药一致性评价.坚定不移地提高国产仿制药质量水平.让广大消费者能够享受质优价廉的好药., beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Fri Oct 20 23:25:58 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254683, encodeId=f7ac2546833a, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Oct 20 23:21:28 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254619, encodeId=693c25461901, content=好消息.值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Fri Oct 20 16:29:36 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1935721, encodeId=e6351935e2128, content=<a href='/topic/show?id=cda0352e61c' target=_blank style='color:#2F92EE;'>#医药企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35276, encryptionId=cda0352e61c, topicName=医药企业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Thu May 17 18:58:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636276, encodeId=f7a416362e600, content=<a href='/topic/show?id=312b35662d6' target=_blank style='color:#2F92EE;'>#十九大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35662, encryptionId=312b35662d6, topicName=十九大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219a22610756, createdName=12498974m58暂无昵称, createdTime=Sun Sep 23 23:58:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256221, encodeId=45842562216e, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Oct 26 22:25:45 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255611, encodeId=321d255611fd, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Tue Oct 24 13:13:54 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255157, encodeId=a30325515e79, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Oct 22 20:07:06 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409126, encodeId=2f691409126a4, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Oct 22 02:58:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456131, encodeId=0fa31456131c9, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Oct 22 02:58:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254689, encodeId=5dbe2546895d, content=总体来看.去除大量的.无效的文号是关键因素.其中.最关键的.就是开展化药仿制药一致性评价.坚定不移地提高国产仿制药质量水平.让广大消费者能够享受质优价廉的好药., beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Fri Oct 20 23:25:58 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254683, encodeId=f7ac2546833a, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Oct 20 23:21:28 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254619, encodeId=693c25461901, content=好消息.值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Fri Oct 20 16:29:36 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
    2017-10-26 1e145228m78(暂无匿称)

    学习了谢谢作者分享!

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1935721, encodeId=e6351935e2128, content=<a href='/topic/show?id=cda0352e61c' target=_blank style='color:#2F92EE;'>#医药企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35276, encryptionId=cda0352e61c, topicName=医药企业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Thu May 17 18:58:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636276, encodeId=f7a416362e600, content=<a href='/topic/show?id=312b35662d6' target=_blank style='color:#2F92EE;'>#十九大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35662, encryptionId=312b35662d6, topicName=十九大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219a22610756, createdName=12498974m58暂无昵称, createdTime=Sun Sep 23 23:58:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256221, encodeId=45842562216e, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Oct 26 22:25:45 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255611, encodeId=321d255611fd, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Tue Oct 24 13:13:54 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255157, encodeId=a30325515e79, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Oct 22 20:07:06 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409126, encodeId=2f691409126a4, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Oct 22 02:58:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456131, encodeId=0fa31456131c9, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Oct 22 02:58:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254689, encodeId=5dbe2546895d, content=总体来看.去除大量的.无效的文号是关键因素.其中.最关键的.就是开展化药仿制药一致性评价.坚定不移地提高国产仿制药质量水平.让广大消费者能够享受质优价廉的好药., beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Fri Oct 20 23:25:58 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254683, encodeId=f7ac2546833a, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Oct 20 23:21:28 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254619, encodeId=693c25461901, content=好消息.值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Fri Oct 20 16:29:36 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
    2017-10-24 情途末路

    学习了.获益匪浅!感谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1935721, encodeId=e6351935e2128, content=<a href='/topic/show?id=cda0352e61c' target=_blank style='color:#2F92EE;'>#医药企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35276, encryptionId=cda0352e61c, topicName=医药企业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Thu May 17 18:58:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636276, encodeId=f7a416362e600, content=<a href='/topic/show?id=312b35662d6' target=_blank style='color:#2F92EE;'>#十九大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35662, encryptionId=312b35662d6, topicName=十九大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219a22610756, createdName=12498974m58暂无昵称, createdTime=Sun Sep 23 23:58:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256221, encodeId=45842562216e, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Oct 26 22:25:45 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255611, encodeId=321d255611fd, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Tue Oct 24 13:13:54 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255157, encodeId=a30325515e79, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Oct 22 20:07:06 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409126, encodeId=2f691409126a4, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Oct 22 02:58:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456131, encodeId=0fa31456131c9, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Oct 22 02:58:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254689, encodeId=5dbe2546895d, content=总体来看.去除大量的.无效的文号是关键因素.其中.最关键的.就是开展化药仿制药一致性评价.坚定不移地提高国产仿制药质量水平.让广大消费者能够享受质优价廉的好药., beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Fri Oct 20 23:25:58 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254683, encodeId=f7ac2546833a, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Oct 20 23:21:28 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254619, encodeId=693c25461901, content=好消息.值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Fri Oct 20 16:29:36 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
    2017-10-22 1e145228m78(暂无匿称)

    学习了谢谢作者分享!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1935721, encodeId=e6351935e2128, content=<a href='/topic/show?id=cda0352e61c' target=_blank style='color:#2F92EE;'>#医药企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35276, encryptionId=cda0352e61c, topicName=医药企业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Thu May 17 18:58:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636276, encodeId=f7a416362e600, content=<a href='/topic/show?id=312b35662d6' target=_blank style='color:#2F92EE;'>#十九大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35662, encryptionId=312b35662d6, topicName=十九大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219a22610756, createdName=12498974m58暂无昵称, createdTime=Sun Sep 23 23:58:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256221, encodeId=45842562216e, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Oct 26 22:25:45 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255611, encodeId=321d255611fd, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Tue Oct 24 13:13:54 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255157, encodeId=a30325515e79, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Oct 22 20:07:06 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409126, encodeId=2f691409126a4, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Oct 22 02:58:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456131, encodeId=0fa31456131c9, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Oct 22 02:58:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254689, encodeId=5dbe2546895d, content=总体来看.去除大量的.无效的文号是关键因素.其中.最关键的.就是开展化药仿制药一致性评价.坚定不移地提高国产仿制药质量水平.让广大消费者能够享受质优价廉的好药., beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Fri Oct 20 23:25:58 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254683, encodeId=f7ac2546833a, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Oct 20 23:21:28 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254619, encodeId=693c25461901, content=好消息.值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Fri Oct 20 16:29:36 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
    2017-10-22 cathymary
  7. [GetPortalCommentsPageByObjectIdResponse(id=1935721, encodeId=e6351935e2128, content=<a href='/topic/show?id=cda0352e61c' target=_blank style='color:#2F92EE;'>#医药企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35276, encryptionId=cda0352e61c, topicName=医药企业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Thu May 17 18:58:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636276, encodeId=f7a416362e600, content=<a href='/topic/show?id=312b35662d6' target=_blank style='color:#2F92EE;'>#十九大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35662, encryptionId=312b35662d6, topicName=十九大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219a22610756, createdName=12498974m58暂无昵称, createdTime=Sun Sep 23 23:58:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256221, encodeId=45842562216e, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Oct 26 22:25:45 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255611, encodeId=321d255611fd, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Tue Oct 24 13:13:54 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255157, encodeId=a30325515e79, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Oct 22 20:07:06 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409126, encodeId=2f691409126a4, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Oct 22 02:58:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456131, encodeId=0fa31456131c9, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Oct 22 02:58:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254689, encodeId=5dbe2546895d, content=总体来看.去除大量的.无效的文号是关键因素.其中.最关键的.就是开展化药仿制药一致性评价.坚定不移地提高国产仿制药质量水平.让广大消费者能够享受质优价廉的好药., beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Fri Oct 20 23:25:58 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254683, encodeId=f7ac2546833a, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Oct 20 23:21:28 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254619, encodeId=693c25461901, content=好消息.值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Fri Oct 20 16:29:36 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
    2017-10-22 hyf030
  8. [GetPortalCommentsPageByObjectIdResponse(id=1935721, encodeId=e6351935e2128, content=<a href='/topic/show?id=cda0352e61c' target=_blank style='color:#2F92EE;'>#医药企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35276, encryptionId=cda0352e61c, topicName=医药企业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Thu May 17 18:58:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636276, encodeId=f7a416362e600, content=<a href='/topic/show?id=312b35662d6' target=_blank style='color:#2F92EE;'>#十九大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35662, encryptionId=312b35662d6, topicName=十九大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219a22610756, createdName=12498974m58暂无昵称, createdTime=Sun Sep 23 23:58:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256221, encodeId=45842562216e, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Oct 26 22:25:45 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255611, encodeId=321d255611fd, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Tue Oct 24 13:13:54 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255157, encodeId=a30325515e79, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Oct 22 20:07:06 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409126, encodeId=2f691409126a4, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Oct 22 02:58:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456131, encodeId=0fa31456131c9, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Oct 22 02:58:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254689, encodeId=5dbe2546895d, content=总体来看.去除大量的.无效的文号是关键因素.其中.最关键的.就是开展化药仿制药一致性评价.坚定不移地提高国产仿制药质量水平.让广大消费者能够享受质优价廉的好药., beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Fri Oct 20 23:25:58 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254683, encodeId=f7ac2546833a, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Oct 20 23:21:28 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254619, encodeId=693c25461901, content=好消息.值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Fri Oct 20 16:29:36 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
    2017-10-20 有备才能无患

    总体来看.去除大量的.无效的文号是关键因素.其中.最关键的.就是开展化药仿制药一致性评价.坚定不移地提高国产仿制药质量水平.让广大消费者能够享受质优价廉的好药.

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1935721, encodeId=e6351935e2128, content=<a href='/topic/show?id=cda0352e61c' target=_blank style='color:#2F92EE;'>#医药企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35276, encryptionId=cda0352e61c, topicName=医药企业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Thu May 17 18:58:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636276, encodeId=f7a416362e600, content=<a href='/topic/show?id=312b35662d6' target=_blank style='color:#2F92EE;'>#十九大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35662, encryptionId=312b35662d6, topicName=十九大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219a22610756, createdName=12498974m58暂无昵称, createdTime=Sun Sep 23 23:58:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256221, encodeId=45842562216e, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Oct 26 22:25:45 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255611, encodeId=321d255611fd, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Tue Oct 24 13:13:54 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255157, encodeId=a30325515e79, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Oct 22 20:07:06 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409126, encodeId=2f691409126a4, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Oct 22 02:58:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456131, encodeId=0fa31456131c9, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Oct 22 02:58:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254689, encodeId=5dbe2546895d, content=总体来看.去除大量的.无效的文号是关键因素.其中.最关键的.就是开展化药仿制药一致性评价.坚定不移地提高国产仿制药质量水平.让广大消费者能够享受质优价廉的好药., beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Fri Oct 20 23:25:58 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254683, encodeId=f7ac2546833a, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Oct 20 23:21:28 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254619, encodeId=693c25461901, content=好消息.值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Fri Oct 20 16:29:36 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
    2017-10-20 1e145228m78(暂无匿称)

    学习了谢谢作者分享!

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1935721, encodeId=e6351935e2128, content=<a href='/topic/show?id=cda0352e61c' target=_blank style='color:#2F92EE;'>#医药企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35276, encryptionId=cda0352e61c, topicName=医药企业)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Thu May 17 18:58:00 CST 2018, time=2018-05-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636276, encodeId=f7a416362e600, content=<a href='/topic/show?id=312b35662d6' target=_blank style='color:#2F92EE;'>#十九大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35662, encryptionId=312b35662d6, topicName=十九大)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219a22610756, createdName=12498974m58暂无昵称, createdTime=Sun Sep 23 23:58:00 CST 2018, time=2018-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=256221, encodeId=45842562216e, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Thu Oct 26 22:25:45 CST 2017, time=2017-10-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255611, encodeId=321d255611fd, content=学习了.获益匪浅!感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/07/17/0ed05bbc4eb124766d2a39104932ec4e.jpg, createdBy=5afd2091871, createdName=情途末路, createdTime=Tue Oct 24 13:13:54 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=255157, encodeId=a30325515e79, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Sun Oct 22 20:07:06 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1409126, encodeId=2f691409126a4, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Sun Oct 22 02:58:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1456131, encodeId=0fa31456131c9, content=<a href='/topic/show?id=3cdb2563088' target=_blank style='color:#2F92EE;'>#企业#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25630, encryptionId=3cdb2563088, topicName=企业)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a765759005, createdName=hyf030, createdTime=Sun Oct 22 02:58:00 CST 2017, time=2017-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254689, encodeId=5dbe2546895d, content=总体来看.去除大量的.无效的文号是关键因素.其中.最关键的.就是开展化药仿制药一致性评价.坚定不移地提高国产仿制药质量水平.让广大消费者能够享受质优价廉的好药., beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7cJ6ejWUr2nIia8qOvAKNdLHr32Df6G8iaoaOx6pHaoiacwp26DaslxZHCGbibZhhCGven4rvmWP60GahtzgFjgCjR/0, createdBy=6b111703011, createdName=有备才能无患, createdTime=Fri Oct 20 23:25:58 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254683, encodeId=f7ac2546833a, content=学习了谢谢作者分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xJXLtMtt5B40XXuPjn9xn1rBhrM6fHLkX1hI86ZoWoPJkgDkZuJNKkBfBHOcRd1fAdezg7JlHNOokohdAp3WkI/0, createdBy=32c81964262, createdName=1e145228m78(暂无匿称), createdTime=Fri Oct 20 23:21:28 CST 2017, time=2017-10-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=254619, encodeId=693c25461901, content=好消息.值得拥有, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59321624668, createdName=zb1235672, createdTime=Fri Oct 20 16:29:36 CST 2017, time=2017-10-20, status=1, ipAttribution=)]
    2017-10-20 zb1235672

    好消息.值得拥有

    0

相关资讯

十九大:与医疗、医生相关荟萃

十九大报告指出,实施健康中国战略。人民健康是民族昌盛和国家富强的重要标志。要完善国民健康政策,为人民群众提供全方位全周期健康服务。作为一名普通的临床医生,要不要看十九大,要不要了解十九大相关内容呢?当然有必要!十九大报告就是未来中国5年,甚至更长的发展指南。只有跟随大环境,跟随国家整体发展的趋势,才能实现自身的发展。因此,我们希望每位临床医生都能了解一些相关信息,这里给大家汇集起来。十九大报告:全

卫生界看大会,说心声,话未来

10月18日,在中国共产党第十九次全国代表大会开幕会上,习近平代表第十八届中央委员会向大会作报告。全国各地、各级卫生计生系统通过组织干部职工集体收看实况转播、微信传阅报告文字等形式,第一时间获取最新信息,感受新时代中国特色社会主义的建设脉搏。从黑龙江到云南,从新疆到广东,从城市大医院到农村卫生室,身处一线的卫生计生工作者认真学习领会报告精神,结合各自实践谈感想、话体会,表示要把党的十九大精神贯彻落

贾立群“党代表通道”回应儿科医生紧缺问题

据“中国之声·大会之声”报道,北京儿童医院超声科主任医师贾立群今天在十九大“党代表通道”回答中国之声记者提问时表示,习近平总书记在十九大报告中明确指出,要深化医疗卫生体制改革,“这一点也包括了儿童的医疗卫生事业的改革。在以前相当一段时间,确实存在着医学院校毕业生不愿意干儿科,当了儿科的医生也出现了很多流失的现象。但近两年来,国务院、国家卫计委推出了很多举措,向儿科医疗方面倾斜,包括提高儿科医务工作

十九大报告:实施健康中国战略 深化医药卫生体制改革

中国共产党第十九次全国代表大会18日在北京人民大会堂隆重开幕。

十九大开幕,习近平:坚持中西医并重,传承发展中医药事业

10月18日,中国共产党第十九次全国代表大会在北京人民大会堂隆重开幕。习近平代表第十八届中央委员会向大会作报告。

十九大代表赵庆华:推进医养结合 期待更多社会力量加入

十九大代表、重医附一院护理部主任赵庆华一直很关注医养结合问题,希望能有更多社会力量参与其中,让老年人病得轻,老得慢,活得好。